AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

AbCellera Biologics Inc.NASDAQ: ABCL

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow turns positive

Q3 FY2026 free cash flow was $25.3M, compared with -$61.52M a year earlier. Trailing-twelve-month free cash flow was -$92.64M.

Context

  • Free cash flow amounted to 231.7% of revenue in FY2025, down 416.7 pp from a year earlier.
  • Free cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly free cash flow holds near $25.3M or moves back toward the trailing-twelve-month quarterly average of -$23.16M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$25.3M+170.3% QoQ
Last fiscal yearDec 2025
-$174.07M-6.9% YoY
LTMSep 2026
-$92.64M-39.5% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+141.1%——
1 year-6.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(174.07M) USD
Year-over-year change
+6.9%

Free Cash Flow vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 free cash flow of $92.64M is the smallest of the 4 companies compared; the peer median is $183.27M.
  • Its year-over-year change of -39.5% is the 3rd highest of 4, against a peer median of +28.3%.
  • Free cash flow amounts to 136.5% of revenue for ABCL, versus a peer median of 640.1%.
ABCL Competitors Peer median
Free Cash Flow for ABCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GENBGenerate Biomedicines, Inc.FY2025$204.13M +68.4%—640.1%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$183.27M -46.9%-16.3%129.7%
ABSIAbsci CorporationLTM Mar 2026$98.51M +28.3%-1.2%5365.2%
ABCLAbCellera Biologics Inc.LTM Sep 2026$92.64M -39.5%—136.5%
Peer median (excluding ABCL) $183.27M+28.3%-8.7%640.1%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
Deferred Income Tax(2.02M)(2.11M)1.96M00
Stock-Based Compensation30.65M49.48M64.18M67.58M55.79M
Change in Working Capital41.67M29.83M13.23M(25.84M)(70.69M)
Accounts Receivables22.48M(22.72M)(45.93M)(75.12M)(55.62M)
Inventory0018.25M00
Accounts Payables1.4M1.07M(15.1M)10.64M3.46M
Other Working Capital17.79M51.47M56.01M38.64M(18.53M)
Other Non-Cash Items3.57M8.55M(7.74M)(84.44M)1.2M
Operating Cash Flow244.58M277.36M(43.88M)(108.56M)(131.3M)
Capital Expenditures(58.45M)(72.66M)(77.51M)(78.4M)(42.77M)
Acquisitions (Net)(11.46M)(25.68M)(13.69M)(19.63M)(7.14M)
Purchases of Investments(322.57M)(781.35M)(1.07B)(765.09M)(453.14M)
Sales of Investments27.61M510.63M910.94M948.81M506.07M
Other Investing Activities32.62M16.43M25.31M35.71M84.72M
Investing Cash Flow(332.25M)(352.63M)(221.11M)121.41M87.75M
Debt Repayment(951K)2.76M11.59M13.5M0
Common Stock Issued4.62M0000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(7.55M)(4.38M)(1.23M)(729K)14.08M
Financing Cash Flow(3.89M)(1.63M)10.36M12.77M14.08M
Effect of Forex Changes(1.43M)(9.6M)589K(2.62M)1.1M
Net Change in Cash(92.97M)(86.49M)(254.04M)23.01M(28.37M)
Free Cash Flow186.13M204.7M(121.38M)(186.95M)(174.07M)

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.